UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15 (d) of the
Securities Exchange Act of 1934
September 19, 2006
Date of Report (Date of earliest event reported)
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
(Exact Name of Registrant as specified in its Charter)
---------------------
Delaware 333-92383 06-1397316
(State or Other Jurisdiction (Commission File Number) (I.R.S. Employer
of Incorporation) Identification No.)
---------------------
251 Ballardvale Street
Wilmington, Massachusetts 01887
(Address of Principal Executive Offices) (Zip Code)
978-658-6000
(Registrant's Telephone Number, including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 2.02. Results of Operations and Financial Condition
The following information shall not be deemed "filed" for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or
incorporated by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set forth by specific
reference in such a filing.
On September 19, 2006, Charles River Laboratories International, Inc. issued
information on its Web site at http://ir.criver.com under "Financial
Reconciliations" that contains financial results for the quarters ended March
26, 2005, June 26, 2005, and September 24, 2005 and for the quarter and fiscal
year ended December 31, 2005, that have been reclassified to reflect the
Company's sale of its Clinical Phase II-IV business and decision to close its
Interventional and Surgical Services business in the second quarter of 2006,
which are now reported as discontinued operations.
ITEM 9.01. Financial Statements and Exhibits
(a) Not applicable.
(b) Not applicable.
(c) Exhibits.
99.1 Financial Results of Charles River Laboratories International,
Inc. for the quarters ended March 26, 2005, June 26, 2005, and
September 24, 2005 and for the quarter and fiscal year ended
December 31, 2005.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended,
we have duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
CHARLES RIVER LABORATORIES
INTERNATIONAL, INC.
Dated: September 19, 2006
By: /s/ Joanne P. Acford
-------------------------------------------
Joanne P. Acford, Corporate Senior Vice
President, General Counsel and
Corporate Secretary
Exhibit Index
Exhibit No. Description
----------- -----------
99.1 Financial Results of Charles River Laboratories International,
Inc. for the quarters ended March 26, 2005, June 26, 2005, and
September 24, 2005 and for the quarter and fiscal year ended
December 31, 2005.